Sapu Nano to Present at the San Antonio Breast Cancer Symposium
AGOURA HILLS, Calif. — Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a pioneering biopharmaceutical firm dedicated to developing transformative cancer treatments, has exciting news. The company’s partner, Sapu Nano, will showcase its novel intravenous formulation of Deciparticle™ everolimus, known as Sapu003, at an upcoming significant event in oncology, the San Antonio Breast Cancer Symposium (SABCS).
Details of the Presentation
The SABCS, a prominent gathering of oncologists and researchers, is scheduled to take place in December at the Henry B. Gonzalez Convention Center. During the event, attendees will learn about Sapu003’s groundbreaking approach to overcoming the limitations of conventional oral mTOR inhibitors, which often struggle with issues like poor bioavailability and inadequate tumor penetration.
Understanding Sapu003: Innovative Nanomedicine
Sapu003 represents a breakthrough in nanomedicine, designed specifically for intravenous delivery. The formulation addresses crucial pharmacologic challenges faced by existing treatments such as Afinitor®. By enhancing bioavailability and reducing toxicity, Sapu003 aims to provide a more effective option for patients suffering from conditions such as hormone receptor–positive (HR+)/HER2– metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET).
Clinical Significance and Study Highlights
Recently accepted abstracts underscore the clinical rationale for using Sapu003. They delve into the molecular biomarkers and pharmacokinetic data that support its efficacy. The ongoing Phase 1 trial focuses on its application in HR+/HER2– metastatic breast cancer, a population that often lacks sufficient treatment options.
FDA Approvals and Implications for Sapu003
The relevance of Sapu003 is further emphasized by existing FDA approvals for similar therapies like everolimus in various cancers. For instance, the FDA has approved everolimus for advanced RCC following the failure of other treatments, based on clinical data that demonstrated significant progression-free survival (PFS) benefits.
Notable Approvals Include:
- Renal Cell Carcinoma (RCC): Approval based on RECORD-1 study results showing PFS improvement.
- Pancreatic NET: Positive outcomes demonstrated in the RADIANT-3 clinical trial.
- Gastrointestinal (GI) and Lung NET: Established benefits in non-functional cases through RADIANT-4 trials.
Collaborative Efforts and Future Directions
This initiative is not solely driven by Sapu Nano. It involves collaborative efforts with organizations like Southern Oncology Clinical Research Unit and Ingenu CRO, emphasizing a unified approach in clinical-translational research. This teamwork fosters molecular biomarker discovery, pharmacokinetic modeling, and GMP manufacturing scalability.
About Oncotelic Therapeutics
Oncotelic, previously known as Mateon Therapeutics, has a rich history dating back to 1988. With a renewed focus on innovative oncology drug development, they aim to improve treatment outcomes, particularly in rarer pediatric cancers. The company holds various designations and continues to explore multiple avenues in cancer treatment, particularly those afflicting children.
Contact Information for Participation
Patients and investigators interested in participating in clinical trials are encouraged to reach out to Ingenu for further information. Oncotelic's dedication to enhancing cancer treatment is evident in their extensive research and outreach efforts.
Australia Headquarters:
22/456 St Kilda Rd
Melbourne 3004 VIC
Australia
Phone: 1300 633 226
Email: hello@ingenucro.com
Presentation Details at SABCS
Session:
December 11 | 5:00 PM – 6:30 PM CST
Frequently Asked Questions
What is Sapu003?
Sapu003 is a Deciparticle™ formulation of everolimus tailored for intravenous usage, designed to enhance drug delivery and efficacy in treating various cancers.
Where will Sapu003 be presented?
Sapu003 will be presented at the San Antonio Breast Cancer Symposium in December, highlighting its innovative approach and clinical trial results.
What cancers does Sapu003 target?
Sapu003 primarily targets hormone receptor–positive metastatic breast cancer, along with renal cell carcinoma and neuroendocrine tumors.
How does Sapu003 differ from traditional treatments?
This formulation aims to overcome limitations of oral mTOR inhibitors, such as poor absorption and toxicity, enhancing overall treatment outcomes.
Who can participate in the clinical trials?
Patients who meet specific criteria related to their cancer diagnosis and treatment history may be eligible for clinical trials involving Sapu003.
